UnitedHealth Group has reached a tentative settlement to resolve a class-action lawsuit alleging that the company, along with other pharmacy benefit managers (PBMs), participated in a scheme to artificially inflate the cost of insulin. The proposed agreement comes as federal scrutiny intensifies regarding the role of intermediaries in the pharmaceutical supply chain and their impact on patient out-of-pocket expenses for life-saving medications, according to legal filings and court records.
The settlement, which requires final approval from a federal judge, follows a broader trend of litigation targeting PBMs—the companies that negotiate drug prices between manufacturers and insurers. While the specific financial terms of the UnitedHealth agreement have not been disclosed, the move follows a similar path taken by CVS Health, which reached its own proposed settlement earlier this year to resolve parallel claims regarding alleged price-gouging tactics. These developments mark a significant shift in how the pharmaceutical industry addresses transparency concerns in the United States healthcare market.
Understanding the Role of Pharmacy Benefit Managers
Pharmacy benefit managers act as the primary middlemen in the American drug market. Their stated purpose is to negotiate rebates and discounts from pharmaceutical manufacturers on behalf of health insurance plans, employers, and government programs. However, critics and plaintiffs in various ongoing lawsuits argue that the current PBM business model creates a perverse incentive structure. By prioritizing medications with higher list prices—which often yield larger rebates—these companies are accused of effectively driving up the actual cost paid by patients at the pharmacy counter.
The core of the litigation against UnitedHealth and its peers centers on the “rebate trap.” Plaintiffs allege that PBMs demand high rebates from drug makers in exchange for placing their products on preferred insurance formularies. Because these rebates are often calculated as a percentage of the drug’s list price, manufacturers are incentivized to maintain or increase that price to keep their products competitive within the insurance network. According to the Federal Trade Commission (FTC) interim report published in July 2024, the concentrated market power of the largest PBMs has allowed them to exert significant control over both access to medication and the prices patients ultimately pay.
Regulatory Scrutiny and Market Impact
The push for accountability extends beyond private litigation. The FTC has launched a comprehensive investigation into the industry, focusing on how PBMs influence drug costs and patient access. In its 2024 staff report, the agency highlighted concerns regarding “opaque” rebate practices that prevent patients from benefiting from lower drug costs. The commission noted that the three largest PBMs now manage nearly 80% of all prescriptions filled in the United States, a level of market concentration that regulators suggest may be hindering fair competition.
For patients, the impact of these pricing strategies is most visible in the cost of insulin, a medication that has been subject to intense public and political debate. While some manufacturers have voluntarily capped out-of-pocket costs for certain products, the litigation suggests that these measures are insufficient as long as the underlying pricing structures remain tied to PBM rebate negotiations. The settlements reached by major players like UnitedHealth and CVS are expected to face rigorous oversight to ensure they address these systemic issues rather than simply serving as a financial resolution to avoid further discovery in court.
What Happens Next for Patients and Stakeholders
The path forward involves several procedural hurdles before any settlement can be considered final. First, the presiding court must conduct a fairness hearing to evaluate the terms of the agreement and ensure that the interests of the affected class—specifically patients who paid high out-of-pocket prices for insulin—are adequately represented. If approved, the settlement will likely mandate changes to how the PBM manages formulary placement and reporting of rebate data, according to legal analysis provided by the Department of Justice regarding similar antitrust matters in the healthcare sector.
Patients currently struggling with the cost of insulin should continue to monitor official communications from their pharmacy benefit provider or the court-appointed administrator for the class action. While these settlements represent a potential milestone in curbing the influence of PBMs, they do not immediately alter the current retail price of medication. For those in need of immediate financial assistance, resources such as the American Diabetes Association’s insulin cost-saving guide remain the primary venue for finding patient assistance programs and manufacturer discounts while the legal proceedings continue.
The court is expected to schedule a hearing in the coming months to review the settlement terms. As the legal process moves toward a resolution, the pharmaceutical industry will likely face continued pressure from both regulators and policymakers to adopt more transparent pricing models. We will continue to update this report as new filings become available. Please feel free to share your thoughts or questions in the comments section below.